All In Biotech

Drug Trial Radar · NCT05755906

A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)

A Randomized, Double-Blind, Parallel Group, Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 374 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

374

Actual

Start

Feb 27, 2023

Primary completion

Nov 19, 2024

Study completion Nov 19, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 12-week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler relative to budesonide metered dose inhaler in adults and adolescents with inadequately controlled asthma.

Conditions

  • Asthma

Interventions

  • BFF MDI 160/9.6 μg BID (320/19.2μg/day)Drug

    Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg BID (320/19.2μg/day)

  • BD MDI 160 μg BID (320 μg/day)Drug

    Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0 to 3 Hours (AUC0-3) at Week 12Time frame: At Week 12

Locations

104 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Chandler, Arizona

  • Research Site

    Mesa, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    Encinitas, California

  • Research Site

    Fresno, California

  • Research Site

    Huntington Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    Northridge, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Jose, California

  • Research Site

    Ventura, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Cutler Bay, Florida

  • Research Site

    DeBary, Florida

  • Research Site

    DeLand, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Plantation, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    South Bend, Indiana

  • Research Site

    Lexington, Kentucky

  • Research Site

    Annapolis, Maryland

  • Research Site

    White Marsh, Maryland

  • Research Site

    North Dartmouth, Massachusetts

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    Rolla, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Kalispell, Montana

  • Research Site

    Missoula, Montana

  • Research Site

    Bellevue, Nebraska

  • Research Site

    Henderson, Nevada

  • Research Site

    Las Vegas, Nevada

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.